CLINICAL TRIALS PROFILE FOR ALBUTEIN
✉ Email this page to a colleague
All Clinical Trials for ALBUTEIN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03451292 ↗ | Effects of Long-Term Administration of Human Albumin in Subjects With Decompensated Cirrhosis and Ascites | Recruiting | Instituto Grifols, S.A. | Phase 3 | 2018-07-24 | This is a phase 3, multicenter, randomized, controlled, parallel-group, and open-label clinical study to evaluate the efficacy of standard medical treatment (SMT) + Albutein 20% administration versus SMT alone in subjects with decompensated cirrhosis and ascites. The study population will consist of subjects being discharged after hospitalization for acute decompensation of liver cirrhosis with ascites (or with prior history of ascites requiring diuretic therapy) with or without acute-on-chronic liver failure (ACLF) at admission or during hospitalization but without ACLF at discharge. |
| NCT03451292 ↗ | Effects of Long-Term Administration of Human Albumin in Subjects With Decompensated Cirrhosis and Ascites | Recruiting | Grifols Therapeutics LLC | Phase 3 | 2018-07-24 | This is a phase 3, multicenter, randomized, controlled, parallel-group, and open-label clinical study to evaluate the efficacy of standard medical treatment (SMT) + Albutein 20% administration versus SMT alone in subjects with decompensated cirrhosis and ascites. The study population will consist of subjects being discharged after hospitalization for acute decompensation of liver cirrhosis with ascites (or with prior history of ascites requiring diuretic therapy) with or without acute-on-chronic liver failure (ACLF) at admission or during hospitalization but without ACLF at discharge. |
| NCT04071041 ↗ | Effect of Albumin Administration in Hypoalbuminemic Hospitalized Patients With Community-acquired Pneumonia. | Recruiting | Institut d'Investigació Biomèdica de Bellvitge | Phase 3 | 2019-10-31 | Community-acquired pneumonia (CAP) remains a leading cause of death world-wide. Hypoalbuminemia is associated with worse outcomes. However, whether albumin administration would have a beneficial effect in outcome in patients with CAP remains uncertain. This project proposes to test the hypothesis of whether the administration of albumin in hypoalbuminemic patients with CAP would increase the proportion of clinical stable patients at day 5. |
| NCT04071041 ↗ | Effect of Albumin Administration in Hypoalbuminemic Hospitalized Patients With Community-acquired Pneumonia. | Recruiting | Instituto de Salud Carlos III | Phase 3 | 2019-10-31 | Community-acquired pneumonia (CAP) remains a leading cause of death world-wide. Hypoalbuminemia is associated with worse outcomes. However, whether albumin administration would have a beneficial effect in outcome in patients with CAP remains uncertain. This project proposes to test the hypothesis of whether the administration of albumin in hypoalbuminemic patients with CAP would increase the proportion of clinical stable patients at day 5. |
| NCT04071041 ↗ | Effect of Albumin Administration in Hypoalbuminemic Hospitalized Patients With Community-acquired Pneumonia. | Recruiting | Jordi Carratala | Phase 3 | 2019-10-31 | Community-acquired pneumonia (CAP) remains a leading cause of death world-wide. Hypoalbuminemia is associated with worse outcomes. However, whether albumin administration would have a beneficial effect in outcome in patients with CAP remains uncertain. This project proposes to test the hypothesis of whether the administration of albumin in hypoalbuminemic patients with CAP would increase the proportion of clinical stable patients at day 5. |
| NCT06052176 ↗ | Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement | Recruiting | Grifols Biologicals, LLC | Phase 2 | 2023-11-02 | Hypothesis: Improvement in cognitive dysfunction with IV albumin in patients with cirrhosis with prior HE and MHE lasts for several weeks after albumin infusion has ended, and is due to persistent improvement in inflammatory markers, endothelial dysfunction, albumin function and gut microbial changes. This will be a single-arm, single-blind sequential trial of IV 25% albumin and IV saline over 8 weeks with biological sampling and cognitive and health related quality of life (HRQOL) testing with each subject acting as their own control. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ALBUTEIN
Condition Name
Clinical Trial Locations for ALBUTEIN
Trials by Country
Clinical Trial Progress for ALBUTEIN
Clinical Trial Phase
Clinical Trial Sponsors for ALBUTEIN
Sponsor Name
